EuroBiotech—More Articles of Note


> Lytix Biopharma rejigged its board of directors ahead of a planned IPO. The changes leave the cancer biotech with a more equal gender split, a requirement for publicly listed companies in its native Norway. Release

> Roche moved its AC Immune-partnered Alzheimer’s candidate into phase 2. The companies are developing the anti-Tau antibody, RG6100, for use in patients with prodromal to mild Alzheimer's disease. Presentation (PDF)

> Antabio raised €7.3 million ($8.7 million). The series A round equips the French biotech to take its inhibitor of bacterial metallo beta-lactamases up to the end of phase 1. Statement

Sponsored By Syneos Health

Blazing a Trail to Clinical Trial Diversity: Four-Part Webinar Series from Syneos Health, Featuring Pharma, Clinical Research and Community Health Leaders

This series will identify obstacles that stifle appropriate patient diversity in trials; unpack the organizational overhaul needed; share how sponsors, patients & investigators have come together to overcome hurdles; and explore how policy innovations can move the industry forward.

> Ablynx set the terms on its $150 million IPO and accompanying $25 million private placement. The listing gives the Belgian biotech a $1.5 billion market cap. Release 

> Silence Therapeutics stepped up its legal action against Alnylam and The Medicines Company. Statement

> Redx revealed it is edging closer to the end of its bankruptcy ordeal. A court is due to hear its application to be rescued as a going concern next week. Release